Top biopharma firms report Q3 market capitalisation decline
European Pharmaceutical Review
DECEMBER 6, 2022
According to a market report by GlobalData, expanding generic drug competition and a drop in demand for COVID-19 vaccines and therapies have lowered the aggregate market capitalisation of the global top 20 biopharmaceutical companies by 9.1 billion in Q3 from its eye disease drug Eylea. percent from $3.45 trillion in Q3 2022.
Let's personalize your content